
Sera Prognostics, Inc. (SERA) Stock Ticker
SERA right now
Market factors today
Unlock the full SERA picture
About Sera Prognostics, Inc.
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
SERA stock facts
| Ticker symbol | SERA |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
| Market cap | $77.1M |
| CEO | Zhenya Lindgardt |
| Employees | 72 |
| Headquarters | Salt Lake City, UT, US |
| IPO date | 2021-07-15 |
| Website | www.sera.com |
What you can see for SERA on Tickr
Live SERA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the SERA report.
Rankings
FAQ
What is the ticker symbol for Sera Prognostics, Inc.?
The ticker symbol for Sera Prognostics, Inc. is SERA, listed on the NASDAQ Global Market.
What is SERA?
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally,…